Core Insights - The successful installation of Asia's first CellXpress.ai in vitro model intelligent factory marks a significant milestone in the strategic collaboration between Danaher Group's Molecular Devices and the Shanghai National Engineering Research Center for Biochips [2][3]. Industry Transformation - The FDA Modernization Act 2.0, enacted in 2022, has fundamentally transformed the preclinical research landscape by recognizing non-animal testing alternatives, allowing the use of organoid models, organ-on-a-chip technologies, and AI algorithms for drug safety and efficacy assessments [3]. - A policy update from the FDA in April 2025 mandates the gradual elimination of mandatory animal testing for specific drugs, integrating organoid and organ-on-a-chip technologies with AI into the regulatory framework [3]. Technological Advancements - The CellXpress.ai platform automates the entire 3D biology process through AI-driven monitoring, cultivation, imaging, and scheduling, significantly reducing manual labor and enhancing efficiency [4]. - Key innovations of the CellXpress.ai system include: - Continuous operation 24/7, ensuring strict control over cultivation and passage schedules, thereby minimizing manual intervention [4]. - Standardized output through AI analysis, providing consistent and physiologically relevant results [4]. - Enhanced growth and expansion efficiency for various stem cell lines and organoids, optimizing screening processes [4]. Broader Implications - The deployment of the CellXpress.ai factory addresses long-standing challenges in the commercialization of organoid technology, such as operational complexity and reproducibility issues [5]. - The integration of organoid technology is expected to accelerate drug development, improving the efficiency of drug safety and efficacy evaluations in response to regulatory demands [5]. - Establishing a national standard for organoid technology is anticipated, promoting the standardized development of this field in China [5]. - The collaboration aims to enhance academic exchanges and training, contributing to the cultivation of high-quality professionals in the organoid industry [5].

OTC2025： 产学研医共促类器官技术突破 类器官技术正在快速发展，并逐步进入临床试验阶段。虽然仍面临挑战，但随着生物工程、人工智能和细 胞培养技术的进步，类器官有望成为精准医疗和再生医学的核心工具，为人类健康带来革命性突破。值此 之际， OTC2025 类器官前沿应用与 3D 培养论坛 重磅来袭：围绕 类器官与疾病建模、 3D 细胞培养、 AI+ 器官芯片推进新药研发、类器官培养及质量控制 等角度展开深度探讨。 论坛名称 ： OTC2025 类器官前沿应用与 3D 培养论坛 02 为何举办OTC2025 1 利用 AI 分析类器官大规模数据 ，加速个性化药物筛选疾病建模； 2 开发 自动化培养系统 ，提高类器官生产效率，降低成本； 3 结合 3D 生物打印和微流控技术，增加类器官的细胞类型和结构复杂度，以更好地模拟人体微环境； 4 研究如何引入血管系统和免疫细胞，增强类器官的功能性； 5 研发临床级培养基和支架材料，减少批次间差异； 6 建立类器官生物库，为临床应用提供稳定的细胞来源。 举办地点 ：上海 论坛规模 ： 50 余授课嘉宾， 800 余参会嘉宾 主办单位 ：上海傲顺医药、上海佰傲泰医药科技、药 ...

Core Insights - Chuangxin International has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [2] - The company focuses on precision medicine, new drug development, and intelligent manufacturing, aiming to overcome key industry bottlenecks and promote the intelligent, standardized, and industrialized development of the organoid industry [2][3] - The FDA's new regulation set to be released in April 2025 will phase out animal testing models, recommending human cell models, including organoids, marking a shift towards more realistic human models in life sciences research [2] Company Overview - Chuangxin International Biotech (Guangzhou) Co., Ltd. was established in March 2018 and has built a comprehensive ecosystem covering the entire lifecycle of organoid technology [2] - The company is positioned as a global leader in organoid technology, redefining core pathways in life sciences research through technological innovation and ecosystem reconstruction [3] - The CEO, Dr. Huang Min, stated that the company will leverage this financing round to enhance its technology platform, data intelligence, and industrial applications, aiming to create a product matrix in key areas such as organoid intelligent devices and data systems [3]

创芯国际董事长兼CEO黄敏表示，感谢粤科基金、投控东海及各投资方的高度认可和战略支持。创芯国 际将以此轮融资为契机，以'技术平台+数据智能+产业应用'三维驱动，构建覆盖类器官全生命周期的技 术生态体系，继续加大核心技术研发、产品创新，在类器官智能设备与芯片、数据智能系统等关键赛道 形成产品矩阵，推动技术突破与产业化升级，致力于成为类器官产业全球领航者。 采写：南都·湾财社记者 徐劲聪 据悉，创芯国际是一家类器官领域全产业链创新企业，依托自主创新的核心技术体系，率先构建了覆盖 类器官全生命周期技术一体化生态平台。公司聚焦精准医疗、新药研发与智能智造三大战略方向，围绕 类器官肿瘤治疗、再生医学、合成生物学三大领域的规模化应用，推动类器官行业向智能化、标准化、 产业化方向发展。 作为联合领投方，广东国资投资机构粤科基金方面表示，创芯国际拥有领先的类器官技术和产业化平 台，其技术成果在精准医疗、新药研发等前沿领域应用价值巨大，符合粤科基金聚焦科技核心赛道的投 资理念，相信创芯国际将在行业变革中占据关键位置。 深投控旗下专注早中期科创企业投资的投控东海表示，认可创芯国际的技术深度与成长潜力。本次投资 不仅是投控东海在生 ...

Core Insights - Organoid technology is a disruptive breakthrough in life sciences, rapidly transitioning from laboratory research to clinical applications, providing new tools for disease mechanism research, drug screening, and personalized treatment [2] - The integration of organoids with automation technology is accelerating the translation of research outcomes into practical applications in precision medicine [2] Event Overview - An online seminar titled "AI Automation Solutions Accelerating Organoid Research and Drug Development" will be held on May 14, 2025, featuring scholars, technical experts, and industry leaders focusing on academic breakthroughs and automation solutions in organoid technology [2] Speaker Highlights - Lin Xinhua, Executive Director of the Guangdong-Hong Kong-Macao Greater Bay Area Precision Medicine Research Institute, will discuss the application of organoids in precision medicine [5] - Lin Delin, Application Technical Support Engineer at Opentrons, will present on Opentrons' organoid automation solutions [5] - Gao Zhengliang, a researcher at Shanghai University School of Medicine, will cover the application of organoids in brain development and diseases [5] Speaker Backgrounds - Lin Xinhua has extensive experience in genetic engineering and precision medicine, with over 80 publications in high-impact journals and a focus on the clinical translation of organoid technology [8] - Lin Delin specializes in automation pipetting technology in biotechnology, with a strong background in biochemistry and molecular biology [11] - Gao Zhengliang has over 20 years of research experience in developmental biology, stem cells, and organoid technology, with numerous publications in prestigious journals [14]

Core Insights - Organoid technology is a disruptive breakthrough in life sciences, rapidly transitioning from laboratory research to clinical applications, providing new tools for disease mechanism research, drug screening, and personalized treatment [2] - The integration of organoids with automation technology is accelerating the translation of research outcomes into practical applications in precision medicine [2] Event Details - An online seminar titled "AI Automation Solutions Accelerating Organoid Research and Drug Development" will be held on May 14, 2025, from 14:00 to 15:30, organized by Opentrons in collaboration with ISCO [2] - The seminar will feature academic scholars, technical experts, and industry pioneers focusing on academic breakthroughs in organoid technology and automation solutions [2] Speaker Information - Lin Xinhua, Executive Director of the Guangdong-Hong Kong-Macao Greater Bay Area Precision Medicine Research Institute, will present on the application of organoids in precision medicine [4] - Lin Delin, Senior Application Technical Support Engineer at Opentrons, will discuss Opentrons' organoid automation solutions [4][8] - Gao Zhengliang, a researcher at Shanghai University School of Medicine, will cover the application of organoids in brain development and diseases [4][11] Additional Engagement - The live event will include interactive segments with exciting prize draws for participants who engage through comments [12][16]

Core Viewpoint - The company, Yinos, is a leading contract research organization (CRO) in the non-clinical safety evaluation sector, providing comprehensive research services that align with both domestic and international standards, and has recently passed a GLP inspection by the FDA, enhancing its international service capabilities [25][26]. Company Overview - Yinos specializes in non-clinical research services for biopharmaceuticals, being one of the earliest companies in China to obtain GLP certifications from NMPA, OECD, and FDA, thus aligning with international standards [3][4]. - The company has a modern facility of nearly 60,000 square meters and a research team of over 1,000, with locations in Shanghai, Nantong, Shenzhen, Huangshan, and San Francisco [4]. - As of December 31, 2024, Yinos has served over 900 pharmaceutical companies and research institutions, contributing to numerous successful drug development cases [4][18]. Financial Performance - In the reporting period, Yinos achieved a revenue of RMB 1,141.67 million, representing a year-on-year growth of 9.94%, while the net profit attributable to shareholders decreased by 24% to RMB 147.78 million [23]. - The proposed profit distribution plan includes a cash dividend of RMB 3.2 per 10 shares, totaling RMB 45.11 million, which accounts for 30.53% of the net profit for the year [1]. Industry Context - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2026, with the market size expected to exceed USD 147.7 billion by 2030 [11]. - In China, the CRO service market is estimated to reach RMB 848.2 billion in 2023, with a projected CAGR of 9.9% from 2023 to 2026 [12]. - The industry is supported by government policies aimed at enhancing drug research and development capabilities, which is expected to drive long-term growth in the CRO sector [13][14]. Technological Advancements - Yinos is investing in artificial intelligence (AI) applications in non-clinical research, aiming to enhance efficiency and reduce costs in drug development processes [19]. - The company is also exploring organoid technology for drug screening and toxicity testing, which is gaining traction in the pharmaceutical research field [19][20]. Strategic Positioning - Yinos has established strong partnerships with leading pharmaceutical companies, positioning itself as a strategic partner in the innovative drug development process [18][21]. - The company is expanding its international presence, having established a subsidiary in the United States to enhance its global market share [22].

Group 1 - The company plans to use up to RMB 700 million of its idle funds for entrusted wealth management, effective from the board's approval date until the next annual board meeting [1][10][52] - The purpose of the entrusted wealth management is to improve the efficiency of idle funds and increase investment returns for the company and its shareholders [2][9] - The funds for this investment will come from temporarily idle self-owned funds, ensuring that the company's normal operations are not affected [3][4] Group 2 - The investment products will primarily include low-risk, high-security financial products, such as fixed-income products and securities, and will not involve stock investments [4][5] - The board has authorized the management to make investment decisions and sign relevant legal documents, with the finance and funding departments responsible for implementation [5][6] - The company will disclose information regarding the purchase of wealth management products in accordance with the regulations of the Shanghai Stock Exchange [6] Group 3 - The company has also approved changes to certain fundraising projects, including adjustments to investment amounts and project timelines, as well as the addition of new projects [18][19][45] - The project "Mode Animal Mouse R&D Breeding Integrated Base Construction" will have its investment amount reduced from RMB 611.13 million to RMB 430.26 million, and the expected completion date will be extended to April 2030 [21][45] - A new project, "AI-driven Organoid and Animal Disease Model Multi-modal Preclinical Drug Research Platform," with an investment of RMB 200 million, has been introduced to enhance the company's R&D capabilities [24][45]